DRUGS & PHARMACEUTICALS LTD.

MANUFACTURERS OF BULK DRUGS & DEALERS OF CHEMICALS & SOLVENTS

GST No.: 27AAACA5253A1Z9 CIN No.: L99899MH1990PLC056538

READ OFFICE :: 1227, HUBTOWN SOLARIS, N. S. PHADKE MARG, OPP. TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA. @: (022) 62872900/2999 E-mail : Info@sareydrugs.com REGD. OFFICE & FACTORY: E-34, M.I.D.C, TARAPUR, BOISAR, DIST.: PALGHAR- 401 506, @: (02525) 652165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

8th January, 2021

To, Dept. of Corporate Services The Bombay Stock Exchange Ltd Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001.

Sub: Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 for quarter ended December, 2020.

Dear Sir/Madam,

We herewith enclose a Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018 received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of our Company.

Please take on record of the same and oblige

Thanking You,

Yours faithfully,

For Aarey Drugs & Pharmaceuticals Ltd

Mihir Ghatalia Managing Director DIN: 00581005

Encl.: a/a

LINK Intime

Link Intime India Pvt. Ltd. CIN: U67190MH1999PTC118368 C-101, 247 Park, L. B. S. Marg, Vikhroli (West), Mumbai - 400 083. Tel.: +91 22 4918 6000 Fax: +91 22 4918 6060 E-mail : mumbai@linkintime.co.in Website : www.linkintime.co.in

Date: 11th January 2021

To The Company Secretary Aarey Drugs & Pharmaceuticals Limited 202/3 Sahakar Bhavan 340/ 48 N N Street, Mumbai-400009

Subject: Confirmation Certificate in the matter of Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

Dear Sir,

In reference to the above captioned regulation, we hereby confirm that the securities received from the depository participants for dematerialisation during the quarter ended 31st December, 2020, were confirmed (accepted/rejected) to the depositories by us and that securities comprised in the said certificates have been listed on the stock exchanges where the earlier issued securities are listed.

SEBI vide their Circular Nos. SEBI/HO/MIRSD/DOP/CIR/P/2020/62 dated April 16, 2020; SEBI/HO/MIRSD/DOP/CIR/P/2020/112 dated June 30, 2020 and SEBI/HO/MIRSD/DOP/CIR/P/2020/142 dated July 29, 2020 had extended the time line/period of exclusion (March 23, 2020 to September 30, 2020) for processing the demat requests by the Issuer Company/RTA. We hereby also confirm that the security certificates received for dematerialisation have been mutilated and cancelled after due verification by the depository participant and the name of the depositories have been substituted in the register of members as the registered owner within the time lines mentioned in the aforesaid circulars.

We request you to kindly take note of the above in your records.

Note: We have not received any demat / remat request during the period 01.10.2020 to 31.12.2020 for Aarey Drugs & Pharmaceuticals Limited. The certificate is issued for compliance purpose only.

Thanking You,

Yours faithfully, For Link Intime India Pvt. Ltd

Mann

Balaji Sharma Vice President- Corporate Registry